Author

Marek Krogulec

Observed names: Krogulec, Marek, M. Krogulec

Observed institutions: Eli Lilly (United States), Stanford Medicine, Albany Medical College, Medical University of Vienna

ORCID: 0000-0002-5698-9706

Observed ORCID: 0000-0002-5698-9706

OpenAlex ID: A5063674909

Baricitinib in Patients with Refractory Rheumatoid Arthritis

2016 · Mark C. Genovese, Joel Kremer, et al. · New England Journal of Medicine · 645

PDF

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

2017 · Roy Fleischmann, Eduardo Mysler, et al. · The Lancet · 519

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial

2019 · Atul Deodhar, Désirée van der Heijde, et al. · The Lancet · 217

Sustained Remission with Etanercept Tapering in Early Rheumatoid Arthritis

2014 · Paul Emery, Mohammed Hammoudeh, et al. · New England Journal of Medicine · 201

Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNFα therapy: a placebo-controlled phase II study

2022 · Claire Daien, Marek Krogulec, et al. · Annals of the Rheumatic Diseases · 35

PDF

Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study

2021 · Jonathan Kay, Janusz Jaworski, et al. · Arthritis Research & Therapy · 32

PDF

Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial

2019 · Chang-Hee Suh, Dae Hyun Yoo, et al. · BioDrugs · 29

PDF

OP0029 Baricitinib, An Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to TNF Inhibitors: Results of the Phase 3 RA-Beacon Study

2015 · M.C. Genovese, J. Kremer, et al. · Annals of the Rheumatic Diseases · 27

Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritis

2021 · Daniel E Furst, Janusz Jaworski, et al. · Rheumatology · 21

PDF

Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47

2024 · Josef S Smolen, Jakub Trefler, et al. · RMD Open · 13

PDF

Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study

2025 · Mark G. Lebwohl, John Y. Koo, et al. · Advances in Therapy · 7

PDF

Efficacy and Safety of Biosimilar CT-P47 Versus Reference Tocilizumab: 1-Year Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study in Patients with Rheumatoid Arthritis

2025 · Gerd Burmester, Jakub Trefler, et al. · Clinical Drug Investigation · 5

PDF

Rheumatoid arthritis oral abstractsO01. Efficacy and Safety of Baricitinib Versus Placebo and Adalimumab in Patients with Moderately to Severely Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Summary Results from the 52-Week Phase 3 RA-Beam Study

2017 · Peter C. Taylor, Marek Krogulec, et al. · Rheumatology · 2

CT-P17 Adalimumab Biosimilar in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Open-Label Extension of a Phase 3 Interchangeability Study

2025 · David M. Pariser, Mark G. Lebwohl, et al. · Dermatology and Therapy · 1

Ab0198 Efficacy and Safety After Transition From Reference Adalimumab to Ct-p17 (adalimumab Biosimilar: 100 Mg/ml) in Comparison With the Maintained Treatment (ct-p17 or Reference Adalimumab) in Patients With Moderate-to-severe Active Rheumatoid Arthritis: 1-year Result

2021 · D. Furst, E. Keystone, et al. · Annals of the Rheumatic Diseases · 1

PDF

Ab0360 Efficacy and Safety of the Prostaglandin Ep4 Receptor Antagonist Cr6086 Added to Methotrexate in Dmard-naïve Early Ra Patients: a Phase 2 Randomized Controlled Trial

2020 · K. Pavelka, I.D. Delina, et al. · Annals of the Rheumatic Diseases · 1

PDF

Efficacy and Safety of Baricitinib Versus Placebo and Adalimumab in Patients With Moderately to Severely Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Summary Results From the 52-week Phase 3 Ra-beam Study

2017 · Peter C. Taylor, Marek Krogulec, et al. · Kölner Universitäts PublikationsServer (Universität zu Köln) · 1

Correction to: Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study

2025 · Mark G. Lebwohl, John Y. Koo, et al. · Advances in Therapy

PDF

2024 · J.S. Smolen, J. Trefler, et al. · Annals of the Rheumatic Diseases

2017 · Peter C. Taylor, Marek Krogulec, et al. · Rheumatology

PDF

Baricitinibe Vs. Pbo E Adalimumabe Na Artrite Reumatoide Mod a Grave ‐ Resultados Do Ra‐beam

2017 · P.C. Taylor, M. Krogulec, et al. · Revista Brasileira de Reumatologia

Efficacité et Tolérance du Baricitinib Chez les Patients Atteints de Polyarthrite Rhumatoïde Active et Présentant une Réponse Inadéquate Aux csDMARDs : Résumé des Résultats de L’étude de Phase 3 de 24 Semaines RA-BUILD

2016 · P. Emery, M. Krogulec, et al. · Revue du Rhumatisme

O51 Efficacy and Safety of Baricitinib in Patients with Active Rheumatoid Arthritis and Inadequate Response to csDmards: Summary Results from the 24-Week Phase III RA-Build Study

2016 · Paul Emery, Marek Krogulec, et al. · Rheumatology

Works count: 27

Citation count: 1,757

H-index: 10

I10-index: 10